PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634482
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634482
Diffuse tenosynovial giant cell tumours (TGCT) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035
D-TGCT is the name of a benign clonal neoplastic growth that arises from synovium. Patients typically have a wide range of symptoms and require multiple surgeries over the course of their lifetime. TGCT is considered an orphan disease because L-TGCT and D-TGCT have documented incidence rates of 30-39 and 5-8 per million person-years, respectively. Both subtypes have a female predisposition (1:1:5) and affect a population that is relatively young. With recurrence rates ranging from 14 to 55%, surgery is now the mainstay of treatment for patients with D-TGCT. Radiosynovectomy and external beam radiation have both been used on their own or in conjunction with surgical excision. A deeper understanding of the etiology of TGCT has opened doors for the development of medical treatments.
Description
D-TGCT is the name of a benign clonal neoplastic growth that arises from synovium. Patients typically have a wide range of symptoms and require multiple surgeries over the course of their lifetime. The discovery that D-TGCT cells overexpress colony-stimulating factor 1 (CSF1), which stimulates the recruitment of polyclonal macrophages, the majority of which possess the CSF1 receptor (CSF1R), has led to the beginning of clinical studies with CSF1R inhibitors. D-TGCT has a significant detrimental effect on patient quality of life. The available options for treating this illness could change if the D-TGCT pathogenetic loop were to be blocked.
Diffuse tenosynovial giant cell tumours (TGCT) (Epidemiology)
TGCT is regarded as an orphan disease because the incidence rates for L-TGCT and D-TGCT are 30-39 and 5-8 per million person-years, respectively. There is a female predisposition (1:1.5), and both subtypes affect a population that is relatively young. Even though TGCT is frequently discovered between the ages of 40 and 60, it can be found at any age, including in children. L-TGCT is typically found in the digits of the hands and feet (85%), whereas D-TGCT is more common in the body's major joints, especially the knee.
Diffuse tenosynovial giant cell tumours (TGCT) -Current Market Size & Forecast Trends
The market for diffuse tenosynovial giant cell tumors (TGCT) is expected to grow significantly, with the global market projected to reach approximately USD 1.5 billion by 2035, up from around USD 500 million in 2023, reflecting a compound annual growth rate (CAGR) of about 11.5%. This growth is driven by increasing awareness of TGCT, advancements in treatment options, and the introduction of targeted therapies such as pexidartinib (Turalio) and vimseltinib, which have shown promising efficacy in clinical trials. The approval of these therapies has opened new avenues for patients with symptomatic TGCT that is not amenable to surgery, addressing a significant unmet medical need. Additionally, the rising incidence of TGCT and improved diagnostic techniques are contributing to market expansion. North America is expected to dominate the market due to its advanced healthcare infrastructure and ongoing research initiatives, while the Asia-Pacific region is anticipated to experience rapid growth as healthcare access improves. Overall, the market for diffuse TGCT is positioned for robust growth through 2035, driven by ongoing innovation and a focus on enhancing patient quality of life.
With recurrence rates ranging from 14 to 55%, patients with D-TGCT are currently mostly treated surgically. Both radiosynovectomy and external beam radiation have been used alone or in conjunction with surgical excision. A deeper understanding of the etiology of TGCT has opened doors for the development of pharmaceutical treatments. In the previous ten years, new pharmacological targets as well as the efficacy and safety of various medications have been studied. Only pexidartinib has currently received FDA approval as a treatment for TGCT. However, the risk/benefit ratio was unbalanced, and it was unclear how long the benefits of the treatment would last, so the EMA rejected the marketing approval of pexidartinib. Vimseltinib (Deciphera Pharmaceuticals), Cabiralizumab (Bristol-Myers Squibb/Five Prime Therapeutics), AMB 051 (Amgen), Emactuzumab (Roche), and other new emerging therapies will soon be readily available on the market and have the potential to propel the market's growth.
Report Highlights
Diffuse tenosynovial giant cell tumours (TGCT) - Current Market Trends
Diffuse tenosynovial giant cell tumours (TGCT) - Current & Forecasted Cases across the G8 Countries
Diffuse tenosynovial giant cell tumours (TGCT) - Market Opportunities and Sales Potential for Agents
Diffuse tenosynovial giant cell tumours (TGCT) - Patient-based Market Forecast to 2035
Diffuse tenosynovial giant cell tumours (TGCT) - Untapped Business Opportunities
Diffuse tenosynovial giant cell tumours (TGCT) - Product Positioning Vis-a-vis Competitors' Products
Diffuse tenosynovial giant cell tumours (TGCT) - KOLs Insight
Table of Content
1. Diffuse tenosynovial giant cell tumours (TGCT) Background
- 1.1. Diffuse tenosynovial giant cell tumours (TGCT) Definition
- 1.2. Signs and Symptoms
- 1.3. Pathogenesis
- 1.4. Clinical Manifestation
- 1.5. Diffuse tenosynovial giant cell tumours (TGCT) biomarkers
- 1.6. Diagnosis
2. Epidemiology Estimated and Forecast to 2035
- 2.1. Epidemiology Research Method & Data Sources Used
- 2.2. United States
- 2.2.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.2.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.3. United Kingdom
- 2.3.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.3.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.4. Spain
- 2.4.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.4.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.5. Germany
- 2.5.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.5.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.6. France
- 2.6.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.6.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.7. Italy
- 2.7.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.7.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.8. Japan
- 2.8.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.8.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.9. China
- 2.9.1. Incident Cases of Diffuse tenosynovial giant cell tumours (TGCT)
- 2.9.2. Diagnosed and treatable cases of Diffuse tenosynovial giant cell tumours (TGCT) by line of therapies (LOT)
- 2.10. Current Unmet Needs in Diffuse tenosynovial giant cell tumours (TGCT)
3. Current Treatment Paradigm
- 3.1. Treatment/Prevention guidelines
- 3.2. Regulatory Approvals/Indication and Current Benchmarks
4. KOLs Insight (US, EU, JP, CH)
- 4.1. Unmet Needs
- 4.2. Analysis of the progress in terms of approvals & current pipeline
- 4.3. Impact on the treatment algorithm and product positioning
- 4.4. Relevance of new targets/platforms/ Therapy Uptake Share %
- 4.5. Physicians Preferences for the new pharmacological agents
5. What's New in 2024/2025
6. Future Treatment Paradigm
- 6.1. Diffuse tenosynovial giant cell tumours (TGCT) Competitor Landscape and Approvals Anticipated
- 6.2. Future Treatment Algorithms and Competitor Positioning
- 6.3. Key Data Summary for Emerging Treatment
7. Late Phase Therapies Strategic Considerations in Diffuse tenosynovial giant cell tumours (TGCT)
8. Total Market Forecast
- 8.1. Key Summary Findings
- 8.1.1. G8 total Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 8.1.2. G8 total Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
9. Market Forecast by Country
- 9.1. United States
- 9.1.1. United States Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.1.2. United States Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.2. Germany
- 9.2.1. Germany Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.2.2. Germany Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.3. France
- 9.3.1. France Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.3.2. France Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.4. Italy
- 9.4.1. Italy Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.4.2. Italy Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.5. Spain
- 9.5.1. Spain Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.5.2. Spain Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.6. United Kingdom
- 9.6.1. United Kingdom Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.6.2. United Kingdom Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.7. Japan
- 9.7.1. Japan Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.7.2. Japan Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
- 9.8. China
- 9.8.1. China Market for Diffuse tenosynovial giant cell tumours (TGCT) 2022-2035 (USD Million)
- 9.8.2. China Market for Diffuse tenosynovial giant cell tumours (TGCT) by Therapies 2022-2035 (USD Million)
10. Market Drivers and Barriers
